Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
Telmisartan linked to reduced risk for Alzheimer’s disease in Black patients
Nov 07, 2022
Black-specific beneficial effects of telmisartan were identified in a Mendelian randomization analysis.
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Whole grain consumption linked to slower global cognitive decline
Nov 22, 2023
For African Americans, those in the highest quintile of whole grain consumption had slower declines in global cognition, perceptual speed and episodic memory.
One in three Alzheimer’s, dementia cases tied to modifiable risk factors
May 11, 2022
Risk factors differ based on sex and race and ethnicity.
Vascular risk factors only explain part of Alzheimer’s disease risk for Blacks, Hispanics
Jan 11, 2023
Barriers to healthcare access and other socioeconomic factors may increase vulnerability in racial/ethnic minorities.
US sets up $300 million database for Alzheimer’s disease research
Apr 05, 2023
In creating the database, the goal is to provide something that can “improve applicability and generalizability of findings.”
Study IDs proportion of dementia cases attributable to known risk factors
Jan 19, 2024
The population-attributable fraction for nongenetic risk factors combined is similar for men and women, but it varies across racial and ethnic groups.
Number of teeth, periodontitis in older adults linked to hippocampal atrophy
Jul 06, 2023
A qualitative interaction was seen between the number of teeth present and the mean periodontal probing depth for symmetric percentage change in left hippocampus.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.